头孢丙烯原料药产业化项目

头孢丙烯原料药产业化项目 一、项目所属地区:东阳 二、项目名称:头孢丙烯原料药产业化项目 三、项目行业:医药化工 四、项目背景和建设条件:头孢菌素在人类医药史上，与青霉素一样有着无与伦比的地位， 已成为目前最大的一类抗生素。我国头孢菌素抗生素是品种少(多以分装为主)，产 量低，尚未形成规模，远远不能满足城乡需要的。头孢丙烯(Cefprozil，CEPZ)是国家 “九五” 计划 项目进度计划表范例计划下载计划下载计划下载课程教学计划下载 研制品种，系新型第二代头孢菌素类口服抗生素，是一高效、低毒、耐 酶的广谱抗菌药 五、项目准备进展情况:我公司是以GCLE为起始原料，经偶合、拆分、纯化等4步反应 得到头孢丙烯成品。 六、建设规模及建设 内容 财务内部控制制度的内容财务内部控制制度的内容人员招聘与配置的内容项目成本控制的内容消防安全演练内容 :根据目前的市场需求，以及我公司的实际情况，建设封闭式化 学合成车间，车间分成若干相对独立的反应区域， 设计 领导形象设计圆作业设计ao工艺污水处理厂设计附属工程施工组织设计清扫机器人结构设计 符合GMP 规范 编程规范下载gsp规范下载钢格栅规范下载警徽规范下载建设厅规范下载 要求。生产规模 为年产8吨，预计该产品上市可新增年产值12000万元，销售收入11500万元，利润 2000万元，税收900万元，创汇700万美元。 七、财务评价:投资总额:1000万美元;引资额:500万美元;投资回收期:4.25年。 八、项目方可提供的条件: 除资金注入外，其他诸如土地、设备、技术都有项目方提供。 外方以资金入股。 九、中方项目单位情况:浙江康裕制药有限公司为普洛药业(股票代码000739)的核心企业， 是一家集研究、开发、生产原料药、制剂、医药中间体及兽药的综合性制药企业，为 国家重点高新技术企业、国家GMP认证企业和浙江省医药工业重点企业。现已通过 ISO14001环境管理体系认证和ISO9001质量管理体系认证，拥有员工1350名，其中各 类专业技术人员占30%以上。公司已连续六年被评为浙江省医药工业"十佳"企业，连续 八年被评为中国银行浙江省分行AAA信用等级企业。氧氟沙星、乌苯美司被认定为浙 江名牌产品，康裕牌商标被认定为浙江省著名商标。 十、联系方式: 联系人姓名:钱永成 邮政编码:322118 联系电话: 传 真: 通讯地址:浙江东阳横店江南西路8号 电子邮箱:kyxmtzb@public.dy.jhptt.zj.cn Dongyang Key Project to Attract Investments ?. Project No.: 11 ?. Project Name: Cefprozil bulk drug, an industrial project ?. Industry to Which the Project Belongs: Pharmaceutical & Chemical Industry ?. Project Background and Construction Conditions: In human pharmaceutical history, Cefprozil has played an unmatched role as Penicillin, and becomes a big one among antibiotics presently. In our country, cephalosporins are of small number of types (mainly engaged in sub-packaging) and of low output, and have not formed into scale production, far from satisfying urban and rural demand. Cefprozil (CEPZ) is a type developed in the National “Ninth Five-Year” Plan. It is one of the second-generation oral antibiotics, and is one of potent, low-toxic, enzyme-resistant, wide-spectrum antimicrobial agents. ?. Project Progression: Taking GCLE as the starting material, our company produces CEPZ through 4-step reactions of coupling, splitting, and purification, etc. ?. Construction Scale and Construction Content: According to the current market demand as well as our company’s actual circumstances, build a close-ended chemical synthesis workshop, which is divided into a number of relatively separate reaction zones, with design complying with the requirements of GMP. The production scale is an annual output of 8 tons. It is expected after marketing the product: new annual production value RMB 120 million yuan, sales revenue RMB 115 million yuan, profit RMB 20 million yuan, tax revenue RMB 9 million yuan, and making profit US $7 million through export. ?. Financial Assessment: Total investment: US $10 million Investment Attracted: US $5 million Recovery Period of Investment: 4.25 years ?. Available Conditions by the Project Party: The project party invests fund, and also provide land, facilities, and techniques. The foreign party becomes a shareholder with fund. ?. Condition of the Chinese Party in the Project: Zhejiang Kangyu Pharmaceuticals Co., Ltd., is the core enterprise of Puluo Pharmaceuticals (stock code: 000739). It is a large-scale comprehensive pharmaceutical enterprise, integrated with research, development, as well as production of bulk drugs, preparations, pharmaceutical intermediates, and veterinary drugs. It is a national key new- and high-tech enterprise, a national enterprise passed verification of GMP, and a key enterprise of Zhejiang Pharmaceutical Industry. Presently, it has passed verification of ISO14001 Environmental Management System and ISO9001 Quality Management System. It has 1350 personnel, including more than 30% of various professionals and technicians among them. It has been recognized as one of the “Ten Top” Enterprises in Zhejiang Pharmaceutical Industry. It has been awarded with the title of “Credit Rating AAA Enterprise” by Zhejiang Branch, Bank of China, for 10 years in succession. Its Ofloxacin and Ubenimex are recognized as Zhejiang Famous Products, and “Kangyu” brand is recongnized as one of Zhejiang Famous Brands. ?. Contact Information: Name of Contact Person: Qian Yongcheng Contact telephone: , Fax: Postal Code: 322118 Correspondence address: No. 8, Jiangnan West Road, Hengdian, Dongyang City, Zhejiang Province E-Mail: kyxmtzb@public.dy.jhptt.zj.cn